Patients with the four most common ABCC6 variants (45.3% of the population) had significant variability in their clinical phenotypes, suggesting that an ABCC6 genotype may not be able to predict the development of GACI vs. PXE. This evidence concerns the gene ABCC6 and pseudoxanthoma elasticum (inherited or acquired).